相关实验视频

Updated: Jun 24, 2025

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

基于脂质纳米颗粒的RNA疗法用于乳腺癌治疗

Luigia Serpico¹, Yuewen Zhu², Renata Faria Maia²

¹Department of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands. l.serpico@umcg.nl.

Drug delivery and translational research

|June 3, 2024

概括

基于RNA的疗法提供了有前途的乳腺癌 (BC) 治疗选择. 脂质纳米颗粒 (LNP) 增强RNA输送,提高疗效和减少副作用,以改善BC治疗中的患者结果.

科学领域:

在瘤学瘤学.
纳米技术纳米技术
生物技术是生物技术.

背景情况:

乳腺癌 (BC) 是一个普遍存在的全球健康问题,目前的化疗和放射治疗等治疗方法在有效性上表现出局限性,并导致严重的副作用.
基于RNA的技术为癌症治疗提供了一个有前途的替代方案,但面临的挑战包括非目标效应和不良稳定性.
脂质纳米粒子 (LNP) 已经成为核酸的有效载体,解决了基于RNA的治疗方法的一些局限性.

研究的目的:

探索基于RNA的乳腺癌 (BC) 治疗技术的最新进展.
突出脂质纳米颗粒 (LNP) 作为BC治疗中RNA的纳米载体的作用.
审查乳腺癌中LNP介导RNA疗法的临床进展.

主要方法:

关于基于RNA的技术和脂质纳米粒子 (LNP) 的最新研究的文献综述.
对专注于乳腺癌 (BC) 模型中的LNP配方和应用研究的分析.
检查使用LNP的基于RNA的疗法临床试验数据和结果.

主要成果:

脂质纳米颗粒 (LNP) 在改善RNA治疗药物的稳定性和向性传递方面显示出显著的潜力.
用LNP封装的RNA配方在临床前乳腺癌 (BC) 模型中显示出增强的疗效.
最近的临床应用表明,基于LNP的RNA疗法在癌症中具有有前途的治疗益处和改善的安全性.

结论:

脂质纳米颗粒 (LNP) 是推动基于RNA的乳腺癌 (BC) 疗法的关键技术.
进一步开发和临床翻译LNP介导RNA策略对于克服当前治疗挑战至关重要.
乳腺癌临床方案为下一代乳腺癌 (BC) 治疗提供了一个可行的平台,具有更好的向性和降低毒性.

关键词:

乳腺癌是什么? 乳腺癌是什么?临床应用临床应用基因治疗是一种基因疗法.脂质纳米颗粒的使用方法通过RNA技术和RNA技术.

更多相关视频

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

相关概念视频

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...